SandboxAQ Startup Diligence Report
SandboxAQ may be a high-upside quantitative-AI platform with credible investors and multidomain deep-tech products, but diligence should validate whether public technical and logo signals convert into repeatable high-margin revenue supporting a $5.6B valuation.
SandboxAQ Startup Diligence Report
SandboxAQ appears eligible as an active private unicorn: CB Insights lists it at $5.6B, company sources show active operations and 2025 funding, and no IPO/acquisition-by-third-party/shutdown signal surfaced in accessible public review. Public evidence supports product breadth, funding strength, leadership/R&D depth and named relationship signals, but financial quality, cap table, customer revenue, retention, contracts, legal/IP and HR records are private.
Public valuation/funding are visible; revenue, ARR, margins, burn and cash are private.
Diligence request: Obtain audited financials, ARR bridge, margins, cash/debt and forecast.
Named logos do not disclose recurring revenue, churn, NRR or concentration.
Diligence request: Request customer revenue, contracts, churn/NRR and references.
Strong public technical claims need independent validation and product-readiness review.
Diligence request: Review benchmarks, model cards, QA, regulatory and acceptance tests.
Healthcare, cyber, defense and international projects create compliance burden.
Diligence request: Counsel to review regulatory, privacy, security, export and insurance.
Large multi-round financings may create preference and governance complexity.
Diligence request: Model preferences, pro-rata rights, option pool, debt and runway.
Defense, healthcare, cyber and energy buyers involve long procurement and validation cycles.
Diligence request: Validate pipeline aging, pilot conversion and procurement paths.
SandboxAQ competes with specialists and incumbents in each vertical.
Diligence request: Run win/loss, technical and pricing benchmarks.
LQM workloads cite AWS, Intel, NVIDIA, Accenture and multi-GPU compute.
Diligence request: Review supplier contracts, COGS, SLAs and alternatives.
Public valuation and financing are strong, but financial statements, projections, cap table, tax/accounting and runway are private.
not publicly verifiable confidence: low
Funding is public, but audited financials, management reports, backlog and AR aging are not public.
| area | public signal | private data needed | risk ids |
|---|---|---|---|
| Revenue/ARR/bookings | Not disclosed. | ARR bridge, bookings, backlog, deferred revenue. | R-001,R-002 |
| Gross margin/COGS | Compute-heavy LQM/HPC signals. | COGS by product and cloud/GPU spend. | R-001,R-010 |
| Cash/runway | >$950M total raised; current cash not public. | Cash, burn, debt and runway. | R-001,R-009 |
| Pricing/ACV | Contact-us/datasheet motion. | Price book, ACV, discounts. | R-011 |
not publicly verifiable confidence: low
The $5.6B valuation implies growth expectations, but projections and assumptions are private.
not publicly verifiable confidence: low
Investor names and private-unicorn eligibility are public; ownership, preferences, debt and options are private.
| item | public evidence | status | diligence need |
|---|---|---|---|
| Named investors | Breyer, Parkway, TIME, T. Rowe Price, Google, NVIDIA, BNP Paribas, Ray Dalio and others. | verified names only | Ownership, preferences and rights. |
| Alphabet/Google relationship | Born at Alphabet; Google added as investor in 2025. | verified public signal | Spinout IP/related-party agreements. |
| Employee equity | Careers page references stock options. | partially_verified | Option plan, grants and pool. |
| Debt/warrants/notes | No schedule public. | not_publicly_verifiable | Debt, SAFE/note, warrant and off-balance-sheet schedule. |
partially verified confidence: medium
Public financing history is partially reconstructable; tax, accounting, off-balance-sheet liabilities and current basis by round are private.
| date | event | amount | valuation | caveat |
|---|---|---|---|---|
| 2022-03-22 | Alphabet spinout / independent company | not_publicly_verifiable | not_publicly_verifiable | Get spinout/financing docs. |
| 2023-02-14 | Public funding headline | $500M headline | not_publicly_verifiable | Confirm terms. |
| 2024-12-18 | Funding at unicorn valuation | >$300M headline not fully body-verified | $5.6B CB / over $5.6B title | Confirm Series E documents. |
| 2025-04-04 | Expanded Series E | >$450M Series E; >$950M total raised | not disclosed in release | Confirm cash runway and preferences. |
SandboxAQ markets LQMs, drug/material discovery, AQNav, AQMed and security tooling; pricing, product economics and independent validation are private.
partially verified confidence: medium
Public product pages verify an active multi-product portfolio, while growth, market share, pricing, cost structure and roadmap timing are not public.
| product | audience | features | status | gap |
|---|---|---|---|---|
| LQMs | Scientific/quantitative enterprise teams | Physics/simulation/quantitative models with LLM interface. | verified positioning | Accuracy and COGS. |
| Drug Discovery | Biopharma R&D | Physics simulation plus ML; enterprise licensing. | partially_verified | Customer outcomes and revenue. |
| Material Discovery | Energy, chemicals, materials | Catalyst, PFAS, battery simulations. | partially_verified | Independent benchmarks. |
| AQNav | Defense/aviation/logistics | GPS-denied magnetic navigation. | partially_verified | Acceptance tests and certification. |
| AQMed/CardiAQ | Hospitals/cardiology | Mobile MCG diagnostics. | partially_verified | Regulatory path and reimbursement. |
| AQtiveGuard/Sandwich | CISOs/developers | Crypto assessment/open-source crypto API. | partially_verified | Adoption, audits and monetization. |
| item | public evidence | status | diligence need |
|---|---|---|---|
| Published list prices | Not found; contact-us/datasheets. | not_publicly_verifiable | Price book and discounts. |
| Enterprise licensing | Drug/material pages describe enterprise licensing. | partially_verified | License, services and GPU pass-through terms. |
| Partner packaging | Accenture service integrated with AQtiveGuard. | verified offering | Rev-share and services margin. |
| Open-source support | Sandwich open source; commercial support not public. | partially_verified | License and support contracts. |
Named relationship signals are broad, but top customers, concentration, churn, revenue and supplier spend are private.
partially verified confidence: medium
Public sources name customers/partners by use case, but not top-15 customers by revenue/application.
| counterparty | relationship | public evidence | status | gap |
|---|---|---|---|---|
| Accenture | Encryption Risk Assessment with AQtiveGuard | Joint release. | verified relationship; revenue private | Contract and pipeline. |
| Aramco | Multi-GPU CFD solver | AI agreement release. | verified relationship; revenue private | Contract value and data rights. |
| U.S. Air Force / defense | AQNav development/testing | AQNav page and contract title. | partially_verified | Contract value and acceptance. |
| UCSF, Mount Sinai West, Mayo Clinic | AQMed studies/collaboration | AQMed page. | partially_verified | Protocols and regulatory status. |
| NOVONIX, AWS, Intel, Accenture, DIC, NVIDIA | Materials/simulation outcomes | Material Discovery page. | partially_verified | Independent validation and contracts. |
partially verified confidence: medium
Accenture, Aramco, Google/NVIDIA investors and clinical/material collaborations are public; terms are private.
| counterparty | relationship | public evidence | status | gap |
|---|---|---|---|---|
| Google and NVIDIA | 2025 Series E investors | April 2025 release. | verified investor signal | Commercial and governance rights. |
| Accenture | Cybersecurity channel/assessment partner | Joint offering. | verified | Channel agreement. |
| Aramco | Energy/chemicals LQM collaboration | Agreement announcement. | verified | Commercial model/IP rights. |
| Clinical/material collaborators | Mayo/UCSF/Mount Sinai and academic/material partners | AQMed/material pages. | partially_verified | Contracts and data rights. |
not publicly verifiable confidence: low
No public revenue-by-customer or concentration disclosure was found.
not publicly verifiable confidence: low
No public severed-relationship disclosure was found; customer losses and failed pilots require private data.
partially verified confidence: medium
Public sources imply cloud/GPU/HPC/open-source and regulated-environment dependencies; supplier spend is private.
| counterparty | relationship | public evidence | status | gap |
|---|---|---|---|---|
| AWS/cloud/HPC | Distributed simulation | 1.1M vCPU PFAS simulation with AWS/Intel/Accenture. | partially_verified | Cloud contract and COGS. |
| NVIDIA/GPU ecosystem | CUDA acceleration and strategic investor | Material page; Series E release. | verified signal | GPU supply/pricing. |
| OpenSSL/BoringSSL/libOQS | Sandwich crypto backends | Sandwich page. | verified | License/security audit. |
| Regulated deployment environments | Clinical, defense, enterprise data settings | AQMed/AQNav/Accenture/Aramco sources. | partially_verified | Data/security/export obligations. |
SandboxAQ breadth is differentiated but exposes the company to specialists and incumbents in each product segment.
partially verified confidence: medium
Competitive axes are technical accuracy, deployment trust, price/TCO, distribution and regulated-market readiness; win/loss and benchmarks are private.
| competitor | segment | overlap | source basis | question |
|---|---|---|---|---|
| Schrödinger | Computational chemistry | Molecular/materials modeling. | Competitor site and SandboxAQ pages. | Accuracy/speed/pricing differentiation? |
| Isomorphic Labs | AI drug discovery | AI-assisted drug discovery. | Competitor site. | Data/outcome differentiation? |
| QuSecure/PQShield | Quantum-safe security | PQC/crypto migration. | Competitor sites and Sandwich/AQtiveGuard. | Enterprise observability/channel advantage? |
| Q-CTRL/sensing specialists | Quantum sensing/navigation | Quantum/AI sensing. | Competitor site and AQNav. | Accuracy/certification versus alternatives? |
| axis | sandboxaq position | pressure | evidence strength | diligence needed |
|---|---|---|---|---|
| Technical performance | 30x hit rate, 35x accuracy, 80x speed and AQNav sorties claimed. | High | medium/company-reported | Independent benchmarks. |
| Distribution | Accenture, Aramco, strategic investors. | Medium-high | medium | Pipeline and partner economics. |
| Price/TCO | No public pricing. | High | low | ACV, discounting, COGS. |
| Regulated readiness | Healthcare, defense, cyber, energy use cases. | High | medium | Certifications and regulatory roadmaps. |
Public GTM appears direct enterprise, partner-led and regulated-market oriented; CAC, pipeline, quotas and budget sufficiency are private.
partially verified confidence: medium
Public GTM evidence includes owned product pages, Accenture, Aramco, AQNav/Air Force signals and publications.
| channel | evidence | role | status | metrics needed |
|---|---|---|---|---|
| Direct enterprise sales | Contact-us/datasheets. | Custom enterprise deals. | verified page behavior | ACV, pipeline, win rate. |
| Partner-led cyber services | Accenture offering. | Co-sell/managed services. | verified | Partner pipeline and rev-share. |
| Strategic collaborations | Aramco/materials/clinical signals. | Pilot-to-production. | partially_verified | Pilot conversion and milestone payments. |
| Government/defense procurement | AQNav/Air Force signal. | Defense contracts/partners. | partially_verified | Contract vehicle and backlog. |
| signal type | examples | status | risk | follow up |
|---|---|---|---|---|
| Funding/investor PR | Google, NVIDIA, BNP Paribas, Ray Dalio; >$950M raised. | verified PR | Investor halo overstates revenue. | Attribution to pipeline. |
| Research/thought leadership | Publications library. | verified | Scientific visibility may not convert. | Map to deals. |
| Partner announcements | Accenture, Aramco, AQNav/Air Force, AQMed, materials partners. | partially_verified | May be pilots/research. | Tie to ARR. |
| Owned channels | Website, blogs, press room, events. | verified presence | Reach/CAC unknown. | Analytics and CAC. |
not publicly verifiable confidence: low
Major-customer status and growth prospects cannot be quantified publicly.
partially verified confidence: medium
Likely avenues include direct sales, partner co-sell, regulated collaborations, defense procurement and research-led demand.
not publicly verifiable confidence: low
Sales compensation, quotas, attainment, sales cycle and sales hiring plan are private.
not publicly verifiable confidence: low
Funding capacity is public, but marketing budget sufficiency, CAC and payback are private.
Public R&D evidence includes leaders, specialists, publications and open-source assets; costs, validation and roadmap commitments are private.
partially verified confidence: medium
Public signals include specialist teams, leadership, publications and Sandwich; full org, budget and key-person dependencies are private.
| name or group | role | evidence | status | gap |
|---|---|---|---|---|
| Jack Hidary | CEO | About page. | verified | Agreement/references. |
| Dr. Stefan Leichenauer | VP Engineering | About page. | verified | Org and retention. |
| Nadia Harhen / Kit Yee Au-Yeung / Luca Ferrara | GMs: AI Simulation, Sensing, Security | About page. | verified titles | P&L ownership. |
| Biopharma core | 70+ specialists; 48+ PhDs | Drug Discovery page. | partially_verified | Roster and credentials. |
| artifact | domain | evidence | status | use |
|---|---|---|---|---|
| EUROCRYPT 2026 item | PQC | Publication library. | verified listing | Crypto depth. |
| AQCat25 | Catalysis/materials | Publication library. | verified listing | Materials differentiation. |
| MCG/JACC item | Medical diagnostics | Publication library. | verified listing | AQMed validation. |
| Sandwich | Cryptography tooling | Page/repo. | verified artifact | Code/security/license review. |
partially verified confidence: medium
Pipeline signals exist for AQCat26, CardiAQ, AQNav and LQM/MCP workflows; dates, costs and critical-path risks are private.
| project | status signal | timing | status | gap |
|---|---|---|---|---|
| AQCat26/catalyst modeling | Coming soon. | not_publicly_verifiable | partially_verified | Committed release date. |
| CardiAQ/AQMed | Studies/collaboration named. | not_publicly_verifiable | partially_verified | Regulatory path. |
| AQNav operationalization | 200+ sorties/500+ hours; Air Force signal. | not_publicly_verifiable | partially_verified | Certification/procurement. |
| LQM-enabled LLM/MCP workflows | Drug/material pages describe integrations. | marketed; roadmap private | partially_verified | Security and COGS. |
Public leadership and careers evidence are meaningful; complete org chart, headcount, compensation, equity, employee relations and turnover are private.
partially verified confidence: medium
A public leadership roster exists; reporting lines below leadership and full org by function/location are private.
partially verified confidence: medium
Careers and biopharma staffing anchors are public; total headcount and hiring plan are not.
| item | public evidence | status | diligence need |
|---|---|---|---|
| Global multidisciplinary team | Careers page lists disciplines and global talent. | verified statement | Headcount by function/location. |
| Biopharma technical core | 70+ specialists; 48+ PhDs. | partially_verified | Roster and credentials. |
| Full-time roles/residency | Careers page invites roles; careers-list role count not rendered. | partially_verified | Open roles and hiring plan. |
| Benefits/retention | Flexible work, benefits, stock options, 401k/pension. | verified statement | Cost and retention effect. |
partially verified confidence: medium
Accessible sources verify names and titles; full biographies and background checks are private.
| name | role | source | status | gap |
|---|---|---|---|---|
| Jack Hidary | CEO | About page | verified | Employment agreement. |
| Eric Schmidt | Chairman, Board of Directors | About page | verified | Board rights. |
| David Silverman | Chief Financial Officer | About page | verified | Finance controls. |
| Andrew McLaughlin | Chief Operating Officer | About page | verified | Operations plan. |
| Stefan Leichenauer, Suzannah Radack, Fernando Dominguez, Nadia Harhen, Kit Yee Au-Yeung, Luca Ferrara | VP/GM leadership roles | About page | verified titles | Span of control and retention. |
not publicly verifiable confidence: low
Benefits and stock options are mentioned publicly; executive compensation and employment agreements are private.
not publicly verifiable confidence: low
Stock options are referenced, but plan size, strike prices, vesting and refresh policies are private.
unverified confidence: low
No significant employee-relations problem was verified publicly; this is not a clearance.
not publicly verifiable confidence: low
No turnover data was public; benefits are described but retention impact is unknown.
| area | public signal | private data needed | risk ids |
|---|---|---|---|
| Compensation | Competitive comp/stock options mentioned. | Agreements, bands, bonus plans. | R-008 |
| Stock plans | Stock options referenced. | Plan, grants, vesting, 409A. | R-008,R-009 |
| Employee relations | No public issue verified; not clearance. | Complaints, investigations, settlements. | R-006,R-008 |
| Turnover | No attrition data disclosed. | Monthly attrition and key losses. | R-008 |
No specific public lawsuit or enforcement action was verified, but healthcare, cyber, defense, international, IP, privacy and contract review needs are significant.
unverified confidence: low
Accessible public review did not verify a pending lawsuit against SandboxAQ; counsel must run formal searches.
| case | forum | filed date | status | request |
|---|---|---|---|---|
| No specific pending lawsuit against SandboxAQ verified | Public web/search review only | not_publicly_verifiable | unverified / no surfaced reliable matter | Run formal docket/counsel review. |
| Employment/IP/customer/regulatory claims schedule | Private legal schedule | not_publicly_verifiable | not_publicly_verifiable | Request counsel representation letter. |
unverified confidence: low
No specific initiated lawsuit by SandboxAQ was verified publicly.
| item | public evidence | status | diligence need |
|---|---|---|---|
| Lawsuits initiated by SandboxAQ | No specific matter verified. | unverified | Federal/state docket search. |
| Regulatory agency actions | No action verified; regulated exposure is public. | partially_verified exposure | Agency correspondence and compliance files. |
| Open-source/security notices | Sandwich exists; vulnerability history not reviewed. | not_publicly_verifiable | SBOM and vulnerability management. |
not publicly verifiable confidence: low
Public pages do not disclose EHS liabilities; healthcare/device and lab/material work creates safety diligence needs.
not publicly verifiable confidence: low
Product marks/open-source assets are visible; full patent/trademark/license ownership is not publicly verifiable.
| asset | location | public status | source | request |
|---|---|---|---|---|
| SandboxAQ/AQNav/AQMed/CardiAQ/AQtiveGuard/Sandwich marks | Public pages | Public use visible; registrations not verified. | Company pages | Trademark docket and assignments. |
| Sandwich open-source library | GitHub/open source | Artifact visible; license/security audit not performed. | Sandwich page/repo | License/SBOM/CLA review. |
| Patents/applications | Google Patents / patent offices | Assignee search insufficient for schedule. | Google Patents search | Patent docket and FTO. |
| Collaborative R&D outputs | Publications/partner projects | Public outputs visible. | Publications/product pages | Joint IP and data rights. |
not publicly verifiable confidence: low
Insurance coverage is not public; cyber, E&O, D&O, product, clinical and government-contract policies should be reviewed.
not publicly verifiable confidence: low
Material contracts are private; public named relationships define the review universe.
| area | public signal | private data needed | risk ids |
|---|---|---|---|
| Material contracts | Named relationships but no terms. | Customer/partner/supplier/government/clinical contracts. | R-002,R-006,R-012 |
| Insurance | No schedule disclosed. | Cyber, E&O, D&O, product liability, clinical/device policies. | R-006 |
| Privacy/security | Privacy/terms/employee notices exist; certifications not public. | SOC2/ISO, pen tests, incidents, data maps. | R-006,R-010 |
| Tax/accounting | No tax/accounting policies disclosed. | Tax returns, NOLs, transfer pricing, revenue-recognition memo. | R-001 |
partially verified confidence: medium
No specific agency problem was verified, but regulated-sector exposure is public and requires specialist review.
| ID | Claim | Status | Sources |
|---|---|---|---|
| EC-001 | CB Insights lists SandboxAQ as a Palo Alto, United States Enterprise Tech unicorn valued at $5.6B with date joined 2024-12-18. | verified high | SRC-001 |
| EC-002 | SandboxAQ publicly describes itself as born at Alphabet and independent since 2022. | verified high | SRC-003 |
| EC-003 | SandboxAQ announced a Series E over $450M and over $950M raised since spinning out from Alphabet. | verified high | SRC-004 |
| EC-004 | A press-room entry links to Bloomberg coverage titled that SandboxAQ raised funds at over a $5.6B valuation. | partially verified medium | SRC-005 |
| EC-005 | A press-room entry links to Crunchbase News coverage titled that SandboxAQ snagged $500M in 2023. | partially verified medium | SRC-006 |
| EC-006 | SandboxAQ positions Large Quantitative Models as AI/quantum tools for real-world quantitative problems. | verified medium | SRC-002 |
| EC-007 | AQNav is marketed for GPS-denied navigation using quantum sensors, AI and Earth magnetic-field signatures, with 200+ sorties and 500+ hours claimed. | partially verified medium | SRC-009 |
| EC-008 | AQMed markets CardiAQ MCG diagnostics and names UCSF, Mount Sinai West and Mayo Clinic clinical-study/collaboration signals. | partially verified medium | SRC-012 |
| EC-009 | The drug-discovery page claims a 70+ specialist biopharma core, 48+ PhDs, and a 250k-to-5.6M molecule expansion with 30x hit rate. | partially verified medium | SRC-010 |
| EC-010 | The material-discovery page names NOVONIX, AWS, Intel, Accenture, DIC and NVIDIA outcomes. | partially verified medium | SRC-011 |
| EC-011 | Sandwich is described as an open-source cryptography API supporting C++, Rust, Python, Go, OpenSSL, BoringSSL and libOQS. | verified medium | SRC-013 |
| EC-012 | Accenture and SandboxAQ announced an expanded partnership around Encryption Risk Assessment integrated with AQtiveGuard. | verified high | SRC-014 |
| EC-013 | SandboxAQ announced an agreement with Aramco to develop a multi-GPU differentiable CFD solver. | verified medium | SRC-015 |
| EC-014 | SandboxAQ careers page describes global multidisciplinary hiring, full-time roles/residency and stock-option benefits. | partially verified medium | SRC-017 |
| EC-015 | SandboxAQ publicly lists senior leaders including Jack Hidary CEO, Eric Schmidt chairman, David Silverman CFO and Andrew McLaughlin COO. | verified high | SRC-003 |
| EC-016 | SandboxAQ maintains a public publications library with 2026 outputs in lattice cryptography, catalysis and magnetocardiography. | verified medium | SRC-019 |
| EC-017 | Public legal/privacy pages exist, but no verified pending litigation or regulatory-enforcement schedule was found in accessible public review. | partially verified low | SRC-020 |
| EC-018 | SandboxAQ faces competition across AI drug/material discovery, post-quantum cybersecurity and quantum sensing/navigation. | verified medium | SRC-009 |
| EC-019 | Public product pricing, ACV, gross margin and package economics are not disclosed. | not publicly verifiable low | SRC-009 |
| EC-020 | Audited financial statements, revenue, ARR, backlog, AR aging, burn and cash runway are not publicly verifiable. | not publicly verifiable low | SRC-004 |
| EC-021 | Shares outstanding, ownership percentages, liquidation preferences, options, warrants, notes and debt are not public. | not publicly verifiable low | SRC-004 |
| EC-022 | Top-customer revenue contribution, churn, retention and contract values are not public. | not publicly verifiable low | SRC-014 |
| EC-023 | Sales productivity, channel mix, pipeline, quota attainment and marketing budget sufficiency are not public. | not publicly verifiable low | SRC-014 |
| EC-024 | R&D roadmap dates, costs, validation plans and release commitments are only partially public. | partially verified medium | SRC-011 |
| EC-025 | Employee relations, attrition, compensation arrangements and incentive-stock-plan details are not public. | not publicly verifiable low | SRC-017 |
| EC-026 | A complete patent/trademark/IP ownership, open-source and license schedule is not publicly verifiable from accessible sources. | not publicly verifiable low | SRC-013 |
| EC-027 | Healthcare, cybersecurity, defense/navigation and international energy work creates regulatory, privacy, security and export-control diligence needs. | verified medium | SRC-012 |
| EC-028 | Public named relationships are traction signals rather than verified revenue. | verified medium | SRC-011 |
| EC-029 | Public evidence supports eligibility as an active private unicorn; no IPO, acquisition-by-third-party or shutdown signal surfaced in accessible review. | verified high | SRC-001 |
| EC-030 | The $5.6B valuation requires diligence against undisclosed revenue and technical execution risk. | not publicly verifiable medium | SRC-001 |
| EC-031 | SandboxAQ has operational dependencies on cloud/GPU/HPC providers, partner channels and regulated customer environments. | verified medium | SRC-011 |
| EC-032 | Tax positions, accounting policies, insurance, material contracts and off-balance-sheet liabilities are not public. | not publicly verifiable low | SRC-021 |
This report is a public-evidence diligence snapshot, not investment advice. Important financial, legal, technical, and contractual facts remain non-public and should be verified directly with management and primary documents before any investment decision.